Citations

Clear

431 citation(s) found for "Schmidt, T".

The Effect of Knee Flexion Contracture on Patient Reported Outcome Measures after Distal Femur Fractures (OTA/AO Type 33):A Multi-Center Prospective Evaluation
Dunbar, Robert P. , Cooke, Margaret E., Born, Christopher T. , Collinge, Cory A. , Egol, Kenneth A., Ertl, William J., Friess, Darin , Gardner, Michael J. , Humphrey, Catherine A. , Jones, Clifford B. , Krieg, James C. , Ostrum, Robert F. , Perez, Edward A., Phieffer, Laura S. , Ricci, William M. , Sems, Andrew, Siegel, Judith A., Teague, David , Zonno, Alan J., Tornetta, Paul , Egol, Kenneth A. , Gardner, Michael J. , Mullis, Brian , Sagi, H. Claude , Schmidt, Andrew H.

Mayo Clinic

No container title available | September 12, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7223366/v1 Get It

Abstract OBJECTIVES: · To determine if patients with knee flexion contracture after distal femur fracture have poorer outcomes than patients who regain full knee extension. · To determine if factors such as patient age, gender, open fracture or implant used favors knee flexion contracture. METHODS: Design: Prospective, multicenter trial Setting: Twenty academic level I trauma centers Patient Selection Criteria: Patients with a distal femur fracture. Patients were evaluated for knee flexion contracture at 3, 6 and 12 months post-operatively. Outcome Measures and Comparisons: SMFA, Bother Index and EQ Health Index scores were recorded. Walking and stair climbing ability were assessed. RESULTS: · 126 patients had radiographic follow up for 12 months. There was clinical follow-up for 99 patients at 3 months, 90 patients at 6 months and 74 pts at 12 months. · Patients with full knee extension had better SMFA scores at 12 months than patients with knee flexion contracture (p = 0.308). · Bother Index (p = 0.29) and EQ Health State (p = 0.12) scores did not demonstrate a difference between patients with or without knee flexion contracture at any time point. · Patients with full knee extension had improved walking ability compared to patients with flexion contracture (p = 0.008). Patients with full knee extension had better stair climbing ability than patients with flexion contracture (p = 0.02). · Only older patient age showed a difference in likelihood of flexion contracture (p = 0.01) The rates of flexion contracture in women versus men (p = 0.51), RIMN versus LLP (p = 0.74) and open versus closed fracture (p = 0.24) were not statistically different. CONCLUSIONS: · Patients with knee flexion contractures after distal femur fracture do worse than patients who regain full extension. · Older patients with distal femur fractures are at greater risk for knee flexion contracture. LEVEL OF EVIDENCE: Level I
Outcomes of Reinduction With Nadofaragene Firadenovec
Schmidt, Bogdana, Horns, Joshua J. , Tyson, Mark D. , Linehan, Jennifer , Dickstein, Rian J., Daneshmand, Siamak , Agarwal, Piyush Kumar , Narayan, Vikram M. , Luckenbaugh, Amy N. , Lotan, Yair

Mayo Clinic

Journal of Urology | August 25, 2025 | Volume: 214 | Issue: 5 | Pages: 472-473

10.1097/ju.0000000000004697 | PMID 40852908 Get It

Paclitaxel neurotoxicity is triggered by epidermal EG5 dependent microtubule fasciculation and X-ROS formation
Rieger, Sandra , Hsieh, Chia-Jung , Anthony, C. Merlyn , Vlach, Mikaela , Cádiz, Antonio , Schmidt, Natalie A. , Ugo, Marie J, Sanchez, Celina Amaya , Reimonn, Cassandra, Wuchty, Stefan , Pellegrini, Adriana D., Brieger, Leah, Pappalardo, Leah G, Regan, Daniel P. , Zhao, Bowen , Dasari, Surendra , Capobianco, Enrico , Lisse, Thomas S. , Staff, Nathan P. , Xu, Xiang‐Xi , Gutierrez, Sergio, Li, Xin , Vlach, Mikaela R , Diaz, Antonio Cadiz , Schmidt, Natalie A , Amaya Sanchez, Maria Celina , Reimonn, Cassandra A , Wuchty, Stefan , Regan, Daniel P , Zhao, Bowen , Zhang, Fuwu , Howell, Caitlin , Hrstka, Sybil C , Dasari, Surendra , Capobianco, Enrico , Lisse, Thomas S , Staff, Nathan P , Xu, Mike Xiangxi , Rieger, Sandra , Hrstka, Sybil , Harrison, Benjamin J. , Gutierrez, Sergio, Li, Xin

Mayo Clinic

No container title available | August 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-5470731/v1 | PMID 40894047 Get It

Abstract Taxanes are frontline chemotherapeutics that stabilize microtubules, induce mitotic arrest, and drive tumor remission. However, their off-target effects in healthy tissues, most notably cutaneous axon degeneration underlying chemotherapy-induced peripheral neuropathy (CIPN), remain poorly understood. Here, we show that paclitaxel induces microtubule fasciculation in epidermal keratinocytes through the mitotic kinesin Eg5, thereby initiating CIPN. Mechanistically, paclitaxel enhances Eg5-dependent fasciculation of detyrosinated (stabilized) microtubules, which constrict and breach the nuclear lamina. This deformation triggers tension-dependent NADPH oxidase-mediated nuclear ROS (X-ROS) formation upstream of mmp13 transcription, a pathway we previously demonstrated drives sensory axon degeneration. Employing a cross-species framework spanning zebrafish, mice, human skin biopsies, and a breast adenocarcinoma cell line, we uncover a conserved paclitaxel–Eg5 mechanism leading to fasciculation of stable microtubules in both healthy epidermis and cancer cells. These findings highlight the dualistic nature of paclitaxel action and underscore the challenge of preserving anticancer efficacy while preventing neurotoxic side effects.
Association Between Transjugular Intrahepatic Shunt (TIPS) and Waitlist Outcomes in Simultaneous Liver Kidney (SLK) Transplant Candidates
Schmidt, Kathryn A. , Meier, Tristan, Cole, Kristin, Olson, Jody C. , Taner, Timuçin , Riad, Samy , Mara, Kristin C. , Schmidt, Kathryn , Riad, Samy M. , Mara, Kristin C , Simonetto, Douglas A. , Meier, Tristan

Mayo Clinic

Clinical Transplantation | August 13, 2025 | Volume: 39 | Issue: 8 | Pages: No page available

10.1111/ctr.70279 | PMID 40802257 Get It

ABSTRACT Background The association between transjugular intrahepatic portosystemic shunt TIPS and waitlist outcomes in simultaneous liver‐kidney (SLK) transplant recipients remains unclear. Methods Between 2003 and 2023, we examined the scientific registry of transplant recipients. All adult candidates with overlapping waiting lists for liver and kidney transplants ( N = 15 087) were analyzed (entire cohort). Candidates without TIPS ( n = 13 980) and with ( n = 1107) were followed through November 30, 2023, and the following outcomes were analyzed: death, SLK transplant, liver‐ or kidney‐alone transplant, or removal from the list. The Aalen–Johansen method was used to calculate the cumulative incidence rates of the outcomes, where the outcomes were considered competing risks. Mixed effects Cox proportional hazard models were used to compare the outcomes by TIPS status. We separately analyzed dialysis‐dependent candidates ( n = 10 370). Results In the entire cohort, the 1‐year cumulative incidence of death in those without TIPS was higher than in those with (12.5% vs. 9%). In the dialysis‐dependent cohort, the 1‐year death incidence was 13.3% versus 8.8% in those without TIPS and those with, respectively. In the multivariable Cox proportional hazard models, TIPS was associated with a 29% lower mortality risk in the entire cohort (HR = 0.71, 95% CI: 0.60–0.84, p < 0.001) and a 33% lower risk of mortality in the dialysis‐dependent cohort. The likelihood of receiving SLK was lower for recipients with TIPS in the univariable analysis. However, this association was attenuated after adjustment. The causes of removal were similar irrespective of TIPS status in both cohorts. Conclusion In this large cohort of SLK candidates, those with TIPS had a better waitlist survival, irrespective of their dialysis requirements before transplantation. Prospective studies are needed to validate these findings.
Lifetime Risk of First Symptomatic ICH or Seizure in Familial Cerebral Cavernous Malformations
Dammann, Philipp , Santos, Alejandro N. , Mavarani, Laven , Chabriat, Hugues , Croft, Jacob , Renteria, Mellisa, Jang, David, Zhang, Jun , Li, Da , Weng, Jiancong , Pilz, Robin A. , Felbor, Ute , Steinberg, Gary K. , Bervini, David , Raabe, Andreas , Rosales, Julieta , Rieß, Christoph , Karadachi, Hannah, Li, Yan , Köhrmann, Martin, Frank, Benedikt , Schmidt, Börge , Overstijns, Manou , Fung, Christian , Zafar, Atif , Nelson, Jeffrey , Zabramski, Joseph M. , Akers, Amy , Kim, Helen , Guey, Stéphanie , Chabriat, Hugues , Herve, Dominique , Zhang, Jun , Weng, Jian-Cong , Rath, Matthias , Steinberg, Gary K , Bervini, David , Rauschenbach, Laurèl , Jabbarli, Ramazan , Beck, Jürgen , Fung, Christian , Al-Shahi Salman, Rustam , Flemming, Kelly D , Lanzino, Giuseppe , Morrison, Leslie , Kim, Helen , Sure, Ulrich , Karadachi, Hanah Hadice , Santos, Alejandro N. , Guey, Stéphanie , Wu, Zhenhua , Petracca, Antonio , Fusco, Carmela , D’Agruma, Leonardo , Castori, Marco , Gu, Jing , Goldberg, Johannes , Cervio, Andrés , Villamil, Facundo , Rauschenbach, Laurèl , Oppong, Marvin Darkwah , Ahmadipour, Yahya , Wrede, Karsten Henning , Jabbarli, Ramazan , Deuschl, Cornelius , Piedade, Guilherme Santos , Wälchli, Thomas , Salman, Rustam Al‐Shahi , Flemming, Kelly D. , Lanzino, Giuseppe , Weinsheimer, Shantel , McCulloch, Charles E. , Sure, Ulrich

Mayo Clinic

Neurology | July 10, 2025 | Volume: 105 | Issue: 3 | Pages: No page available

10.1212/wnl.0000000000213798 | PMID 40638881 Get It

Exogenous Hormones, Tumor Intrinsic Subtypes, and Breast Cancer
Cornet, Charlotte Le , Truong, Thérèse, Bolla, Manjeet K. , Koutros, Stella, Stone, Jennifer , Shulman, Katerina, Aronson, Kristan J. , Guénel, Pascal, Patel, Alpa V , Bodelón, Clara , Teras, Lauren R., Shahi, Shamim , Dossus, Laure, Kaaks, R., Holleczek, Bernd , Hoppe, Reiner , Czene, Kamila, Hall, P.F., Mannermaa, Arto, Wu, Anna H. , Obi, Nadia , Panayiotidis, Mihalis I. , Haiman, Christopher A., Shu, Xiao , Perou, Charles M. , Alsten, Sarah Van, Eliassen, A. Heather, Kraft, Peter, Ahearn, Thomas U., Evans, D. Gareth , Wolk, Alicja, Easton, Douglas F., Pharoah, Paul D. P., Vachon, Celine M. , Chang-Claude, Jenny, Evans, D Gareth , Perou, Charles M , Stone, Jennifer , Panayiotidis, Mihalis I , Jung, Audrey , Behrens, Sabine , Middha, Pooja , Truong, Thérèse , Jernström, Helena , Wang, Qin , Southey, Melissa C. , Freeman, Laura E. Beane , Koutros, Stella , Rennert, Gad , Murphy, Rachel A. , Guénel, Pascal , Teras, Lauren R. , Lacey, James V. , Dossus, Laure , Kaaks, Rudolf , Brenner, Hermann , Brauch, Hiltrud , Czene, Kamila, Mannermaa, Arto , Michailidou, Kyriaki , McLean, Catriona , Haiman, Christopher A., Augustinsson, Annelie , Zheng, Wei , Troester, Melissa A. , Abubakar, Mustapha , Ahearn, Thomas U., Wolk, Alicja , Milne, Roger L. , Easton, Douglas F. , Schmidt, Marjanka K. , García‐Closas, Montserrat , Vachon, Celine M. , Fortner, Renée T. , Chang‐Claude, Jenny

Mayo Clinic

JAMA Network Open | July 7, 2025 | Volume: 8 | Issue: 7 | Pages: e2519236

10.1001/jamanetworkopen.2025.19236 | PMID 40622713 Get It

ImportanceEtiologic heterogeneity in breast carcinogenesis needs to be well characterized for targeted prevention. Associations between menopausal hormonal therapy (MHT) and oral contraceptive (OC) use and breast cancer intrinsic-like subtypes are not well understood.ObjectiveTo examine whether exogenous hormone use is differentially associated with breast cancer subtypes and to evaluate heterogeneity by intrinsic-like subtypes.Design, Setting, and ParticipantsThis study pooled data from 31 nested and population-based case-control studies involved in the Breast Cancer Association Consortium. The study population included individuals with breast cancer and control participants from 13 case-control studies nested in prospective cohorts (recruited between 1982 and 2011) and 18 population-based case-control studies (recruited between 1990 and 2013). Data analysis was performed in June 2024.ExposureMHT use (estrogen-progestin therapy [EPT] or estrogen-only therapy [ET]) in postmenopausal women and OC use in premenopausal women (never, past use, or current use).Main Outcomes and MeasuresBreast cancer intrinsic-like subtypes (luminal A–like, luminal B–like, luminal B–ERBB2 [formerly HER2 or HER2/neu]-like, ERBB2 enriched–like, or triple-negative) were determined by immunohistochemistry of tumor sections. Polytomous logistic regression was performed to estimate the association between exogenous hormones and risk of breast cancer by intrinsic-like subtypes. Analyses by subtypes were stratified by body mass index (BMI [calculated as weight in kilograms divided by height in meters squared]; healthy weight, 18.5-&amp;lt;25; overweight, 25-&amp;lt;30; or obesity, ≥30).ResultsThis study included 42 269 individuals with breast cancer (11 901 [28.2%] premenopausal and 30 368 [71.8%] postmenopausal; 23 353 [55.2%] had a known intrinsic-like subtype) and 71 072 control participants. The mean (SD) age of all participants was 57.9 (10.9) years. In postmenopausal women, associations between current MHT use (EPT or ET) and breast cancer differed by subtype. Current EPT users with healthy weight were more likely to be diagnosed with luminal A–like (odds ratio [OR], 2.51 [95% CI, 2.26-2.80]) or luminal B–ERBB2-like (OR, 1.95 [95% CI, 1.61-2.37]) subtypes. These associations were attenuated but remained for individuals with overweight (OR, 1.40 [95% CI, 1.02-1.92]) or obesity (OR, 1.68 [95% CI, 1.01-2.78]). EPT use increased the odds of being diagnosed with luminal B–like tumors solely in women with healthy weight (OR, 1.47 [95% CI, 1.17-1.86]). Current ET use was positively associated with luminal A–like disease in women with healthy weight only (OR, 1.16 [95% CI, 1.01-1.32]), showing inverse associations with higher BMI (obesity: OR, 0.65 [95% CI, 0.50-0.85]). In premenopausal women, recent OC use was associated with luminal B–ERBB2-like (OR, 1.50 [95% CI, 1.09-2.08]), ERBB2 enriched–like (OR, 2.33 [95% CI, 1.55-3.51]), and triple-negative (OR, 1.75 [95% CI, 1.33-2.29]; P &amp;lt; .04 for heterogeneity) tumors.Conclusions and RelevanceIn this study, clear differences were observed in associations between current EPT use and luminal-like breast cancer subtypes and other subtypes. EPT users with healthy weight were more likely to be diagnosed with luminal-like breast cancer compared with nonusers. Subtype heterogeneity was less apparent in associations of OC and ET use. Future studies on contemporary formulations, patterns of use, and routes of administration of exogenous hormone usage are warranted.
Enhanced Risk Stratification of Smoldering Multiple Myeloma with Dynamic Biomarkers: A Multinational, Multicenter Study including 2,270 Participants (PANGEA 2.0)
Chabrun, Floris , Schwartz, Daniel L. , Gentile, Susanna, Elias, K. , Gupta, Tulika , Perry, Jacqueline , Santos, David M. Cordas dos , Hielscher, Thomas , Werly, Annika, Schmidt, Sophia, Liacos, Christine‐Ivy , Kanellias, Nikolaos , Gisbert, Noelia Collado, Chavda, Selina J , Ainley, Louise , Magistris, Claudio De, Pettine, Loredana , Timonian, Michael , Tobia, Catherine, Phan, Sally, Lamb, Jennifer, Silverio, Maria-Theresa, O’Donnell, Elizabeth , Mateos, María‐Victoria , Kumar, Shaji , Kastritis, Efstathis, Trippa, Lorenzo , Mai, Elias K , Santos, David Cordas Dos , Timonian, Michael , Alberge, Jean-Baptiste , Bolli, Niccolo' , Yong, Kwee , Kortüm, Martin , Einsele, Hermann , Mateos, María-Victoria , Kumar, Shaji K , San-Miguel, Jesus , Paiva, Bruno , Dimopoulos, Meletios A , Raab, Marc S , Ghobrial, Irene M , Schwartz, Daniel S. , Gentile, Susanna , Gupta, Tulika R. , Perry, Jacqueline, Schmidt, Sophia K., Theodorakakou, Foteini , Fotiou, Despina , Liacos, Christine Ivy, Martín‐Sánchez, Esperanza , Termini, Rosalinda , Waldschmidt, Johannes M , Ainley, Louise, Vià, Matteo Da , Alberge, Jean-Baptiste , Patel, Vidhi, Costello, Patrick , Tobia, Catherine, Phan, Sally, Lamb, Jennifer, Silverio, Maria-Theresa, Davis, Maya, Marinac, Catherine R. , Nadeem, Omar , Bolli, Niccolò , Yong, Kwee , Kortüm, K. Martin , Miguel, Jesús F. San , Paiva, Bruno , Kastritis, Efstathios , Dimopoulos, Meletios Α. , Raab, Marc S. , Ghobrial, Irene M.

Mayo Clinic

No container title available | June 3, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-6696313/v1 | PMID 40502745 Get It

Abstract Accurate prediction of risk of progression from smoldering (SMM) to active multiple myeloma (MM) is paramount to individualized early therapeutic strategies with minimum risk of overtreatment. Current risk stratification models do not account for evolving biomarker trajectories. We assembled the largest cohort to date of 2,270 SMM patients from six international centers with longitudinal clinical and biological data to train and validate the PANGEA 2.0 risk models. Four evolving biomarkers were significantly associated with shorter time-to-progression: M-protein increase ≥0.2g/dL, involved:uninvolved serum free light chain ratio increase ≥20, creatinine increase >25%, and hemoglobin decrease ≥1.5g/dL. PANGEA 2.0 outperforms established models including the 20/2/20 and IMWG models by more accurately predicting progression (C-statistics=0.69–0.84), even without biomarker history (C-statistics=0.69–0.83) or recent bone marrow biopsy. PANGEA 2.0 is an easy-to-use, open-access tool (https://ghobrial.shinyapps.io/pangea_2_calculator) to improve and individualize SMM risk stratification. Validation tools are available to compare PANGEA 2.0 to established models (https://ghobrial.shinyapps.io/pangea_validation).
Outcomes of medical and surgical management in infectious intracranial aneurysms: a multicenter cohort analysis
Alawieh, Ali , Zohdy, Youssef M. , Koo, Andrew B. , Saad, Hassan , Baba, Bachar El , Newman, Sarah, Grossberg, Jonathan A , Matouk, Charles , Cawley, C. Michael, Reisner, Andrew , Perez‐Vega, Carlos , Burkhardt, Jan‐Karl , Salem, Mohamed M , Jabbour, Pascal , Naamani, Kareem El, Gooch, M Reid, Starke, Robert M., Abdelsalam, Ahmed , Lu, Victor M , Chalhoub, Reda , Spiotta, Alejandro M , Alawieh, Ali M , Zohdy, Youssef M , Koo, Andrew B , El Baba, Bachar , Grossberg, Jonathan A , Matouk, Charles , Fox, W Christopher , Perez-Vega, Carlos , Jabbour, Pascal , Levitt, Michael R , Chalhoub, Reda M , Spiotta, Alejandro M , Howard, Brian M , Burkhardt, Jan‐Karl , Dimisko, Laurie , Pradilla, Gustavo , Naamani, Kareem El , Schmidt, Richard F. , Gooch, Michael Reid , Abdelsalam, Ahmed, Levitt, Michael R. , Kobeissy, Firas , Barrow, Daniel L.

Mayo Clinic

Journal of NeuroInterventional Surgery | May 23, 2025 | Volume: 18 | Issue: 4 | Pages: 1079-1086

10.1136/jnis-2025-023421 | PMID 40409986 Get It

Introduction Infectious intracranial aneurysms (IIAs) are rare but serious complications of systemic infections, particularly infective endocarditis. These aneurysms are prone to rupture, leading to significant morbidity and mortality. Management strategies lack consensus due to the rarity of the condition and reliance on small case series. This study examines the clinical management of IIAs using data from a large multicenter cohort. Methods A retrospective registry-based cohort study was conducted across 11 tertiary care centers in the USA between 2018 and 2023. Patients with IIAs were identified based on clinical and radiographic criteria. The primary outcome was treatment failure defined as persistence, growth, or rupture of the aneurysm. Secondary outcomes were mortality and the modified Rankin Scale (mRS) score at 90 days and 1 year. Multivariate logistic regressions were used to identify outcome predictors. Results A total of 104 patients with 166 aneurysms were included, with a median age of 43 years. Medical management was successful in 56% of cases, with failure often within 18 days of initiation. Predictors of failure included younger age, larger aneurysm size, and rupture at presentation. Surgical and endovascular interventions achieved higher success rates with better outcomes. At 90 days, 57% of patients achieved functional independence (mRS 0–2), while the mortality rate was 24%. Conclusion This study highlights the limitations of medical management for IIAs and underscores the need for early surgical or endovascular intervention in high-risk patients. Outcome predictors aid clinical decision-making, optimizing patient management. Further research is needed to standardize management guidelines for IIAs.
Simultaneous ultra-high resolution multi-energy cardiac imaging in a dual-source photon counting detector CT system
Shanblatt, Elisabeth R. , Swicklik, Joseph R., Allmendinger, Thomas , Schmidt, Bernhard , Flohr, Thomas , McCollough, Cynthia H. , Leng, Shuai , McCollough, Cynthia H , Leng, Shuai , Rajendran, Kishore

Mayo Clinic

British Journal of Radiology | March 30, 2025 | Volume: 98 | Issue: 1175 | Pages: 1873-1879

10.1093/bjr/tqaf069 | PMID 40156139 Get It

Abstract Objectives To assess quantitative and qualitative image characteristics in phantoms and patients using a simultaneous ultra-high resolution (UHR) and multi-energy (ME) dual-source cardiac scan mode in a photon counting detector (PCD) CT scanner. Methods UHR-ME cardiac scans were performed to determine the spatial resolution and multi-energy performance. UHR reconstructions were completed to measure transverse and axial spatial resolution in terms of modulation transfer function (MTF) and slice sensitivity profile (SSP). Virtual monoenergetic images (VMIs), virtual non-contrast (VNC) images, and iodine concentration images were created using moderately sharp reconstruction kernels to assess ME performance. With IRB approval, coronary CT angiograms were acquired in 19 patients using the UHR-ME mode, from which iodine contrast-to-noise ratio (CNR) was measured. Various ME post-processing tasks were performed to show the utility of the spectral capabilities. Results VMIs showed a mean CT number error of 6.0%, while iodine accuracy was 0.71 mg/cc (root-mean-square-error). Spatial resolution matched well with a standard UHR mode. Patient images showed a trend of higher CNR at lower keV, while higher keV images showed decreased calcium blooming. ME techniques to separate iodine and calcium were used successfully. Conclusions The combination of UHR-ME cardiac mode retains UHR image quality while providing flexibility for ME post-processing. Advances in knowledge Cardiac UHR-ME PCD-CT scanning offers simultaneous UHR and ME imaging without loss of spatial or temporal resolution or quantitative accuracy.